Published in Products

BioTissue launches CAM360 AmnioGraft regenerative therapy

This is editorially independent content
4 min read

BioTissue, Inc. is introducing its newest cryopreserved amniotic membrane (CAM) solution to the company’s product lineup: CAM360 AmnioGraft (AG), intended for dry eye disease (DED) and other ocular surface conditions.

Let’s start with BioTissue.

Founded in 1997 and headquartered in Miami, Florida, the biotechnology company is a developer of products derived from cryopreserved human amniotic and umbilical cord tissues.

The portfolio: Among BioTissue’s CAM products is the CryoTek, its proprietary cryopreservation technology, designed to maintain tissue’s structural and functional integrity.

  • Note: These products are currently the only amniotic grafts that are FDA-cleared for their therapeutic properties in repairing and healing ocular surface inflammation, according to the company.

Exactly how can CAM be used?

Notable among BioTissue’s products is the self-retained Prokera Slim, the only FDA-cleared therapeutic device using CAM for treating anti-inflammation, anti-scarring, and promoting damaged eye surface healing associated with ocular surface disease (OSD).

See here for our coverage of its efficacy in providing short-term treatment for moderate-to-severe DED.

Plus: Read our rundown on the long-term data supporting the use of the TissueTuck sutureless technique with BioTissue’s CAM during pterygium excision surgery.

Give me some more clinical data.

Prior research has identified the benefits of CAM products for reducing DED symptoms.

Case in point: A 2017 randomized clinical study (NCT02764814) evaluated its efficacy vs conventional maximum treatment in DED patients following 3 months of follow-up.

  • The results: Self-retained CAM was found to be a “promising therapy for corneal nerve regeneration and accelerated recovery of the ocular surface health” for DED.

Also: A 2018 study published in Clinical Ophthalmology—the “DRy Eye Amniotic Membrane” (DREAM) study—analyzed CAM’s efficacy among patients with refractory DED following 3 months of follow-up.

  • Those results: CAM placement was found to be “promising to enhance the recovery of ocular surface health” and reduced DED symptoms for moderate-to-severe DED.

Alrighty … now talk about this new CAM.

Designed as a ringless CAM with no need for refrigeration, the CAM360 AG is marketed as the only hydrated CAM that provides the following properties for ocular use:

  • Anti-inflammatory
  • Anti-scarring
  • Anti-angiogenic

Note: While similar to the properties mentioned above for other CAMs, those were not also hydrated.

Give me some features.

The CAM is shelf-stable due to the use of BioTissue’s proprietary SteriTrek technology, a unique preservation process that protects the tissue’s bioactive components while also maintaining its natural hydration.

Plus: Adhesive properties ensure its position is secure under a bandage contact lens (BCL).

  • The intended result: Optimal patient comfort and treatment efficacy to enable patients to resume normal daily activities.

Can you go into specifics on its efficacy?

Aside from reducing DED signs and symptoms, the CAM is also reported to support epithelial adhesion and differentiation as well as promote corneal nerve regeneration (as with BioTissue’s previous CAMs).

Can it be used for any other conditions other than dry eye?

Yes! Its other applications include:

  • Superficial punctate keratitis (SPK)
  • Ocular surface optimization
  • Glaucoma-medication-induced dry eye
  • Neurotrophic keratitis stage 1

Nice! Lastly … how can I add this to my practice?

Click here to request details from the company.

And if you’re a patient, click here to search for surgeons nearby offering the CAM360 AG.

Editor's note: This article was updated on June 10, 2024.

How would you rate the quality of this content?